Crescent Biopharma, Inc. (CBIO) |
| 19.52 1.53 (8.5%) 04-14 16:00 |
| Open: | 17.87 |
| High: | 19.895 |
| Low: | 17.72 |
| Volume: | 585,400 |
| Market Cap: | 538(M) |
| PE Ratio: | -1.52 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 24.04 |
| Resistance 1: | 20.58 |
| Pivot price: | 17.09 |
| Support 1: | 13.98 |
| Support 2: | 9.90 |
| 52w High: | 29 |
| 52w Low: | 8.72 |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Financials
| EPS | -12.810 |
| Book Value | 5.990 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.393 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -843.71 |
| Return on Assets (ttm) | -69.2 |
| Return on Equity (ttm) | -160.8 |
Company news
Fri, 27 Mar 2026
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
Fri, 27 Mar 2026
Three new Crescent Biopharma hires get stock options at $13.50 - Stock Titan
Sat, 28 Feb 2026
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Thu, 19 Feb 2026
New hires at Crescent Biopharma get 10-year stock options - Stock Titan
Wed, 18 Feb 2026
Crescent Biopharma doses first patient in ASCEND cancer trial - Investing.com
Thu, 05 Feb 2026
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
